relay therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. by placing protein motion at the heart of drug discovery, relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. headquartered in cambridge, mass., relay therapeutics is a private company launched in 2016. to date, relay therapeutics has raised $120m in financing from third rock ventures, bvf partners, gv (formerly google ventures), an affiliate of d.e. shaw research, casdin capital, ecor1 capital, section 32 and alexandria venture investments. our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. if you're creative, collaborative and passionate
Company profile
Ticker
RLAY
Exchange
Website
CEO
Sanjiv K. Patel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Relay Securities Corporation • Relay ML Discovery, LLC ...
RLAY stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
22 Feb 24
424B7
Prospectus with selling stockholder info
10 Jan 24
D
$30.00 mm in equity, sold $30.00 mm, 1 investor
10 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
424B7
Prospectus with selling stockholder info
16 Nov 23
Latest ownership filings
4
Thomas Catinazzo
29 Mar 24
4
Donald A Bergstrom
29 Mar 24
4
Peter Rahmer
29 Mar 24
4
Brian Adams
29 Mar 24
SC 13G/A
Casdin Capital, LLC
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Peter Rahmer
31 Jan 24
4
Thomas Catinazzo
31 Jan 24
4
Donald A Bergstrom
31 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 154.04 mm | 154.04 mm | 154.04 mm | 154.04 mm | 154.04 mm | 154.04 mm |
Cash burn (monthly) | (no burn) | 16.93 mm | 24.53 mm | 29.47 mm | 25.13 mm | 22.35 mm |
Cash used (since last report) | n/a | 116.97 mm | 169.43 mm | 203.60 mm | 173.62 mm | 154.41 mm |
Cash remaining | n/a | 37.06 mm | -15.40 mm | -49.56 mm | -19.59 mm | -371.75 k |
Runway (months of cash) | n/a | 2.2 | -0.6 | -1.7 | -0.8 | -0.0 |
Institutional ownership, Q3 2023
97.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 169 |
Opened positions | 22 |
Closed positions | 12 |
Increased positions | 67 |
Reduced positions | 46 |
13F shares | Current |
---|---|
Total value | 1.08 tn |
Total shares | 128.92 mm |
Total puts | 10.70 k |
Total calls | 95.60 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
SB Investment Advisers | 27.90 mm | $234.68 bn |
Vanguard | 10.55 mm | $88.75 bn |
T. Rowe Price | 8.61 mm | $72.87 bn |
BLK Blackrock | 8.33 mm | $70.05 bn |
Casdin Capital | 6.92 mm | $58.23 bn |
JPM JPMorgan Chase & Co. | 5.14 mm | $43.20 bn |
STT State Street | 4.91 mm | $41.26 bn |
BLVGF Bellevue | 4.89 mm | $41.08 bn |
EcoR1 Capital | 4.16 mm | $35.02 bn |
ArrowMark Colorado | 3.81 mm | $32.05 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Bergstrom Donald A | Common Stock | Sell | Dispose S | No | No | 7.7 | 765 | 5.89 k | 530,113 |
27 Mar 24 | Adams Brian | Common Stock | Sell | Dispose S | No | No | 7.7 | 348 | 2.68 k | 327,390 |
27 Mar 24 | Thomas Catinazzo | Common Stock | Sell | Dispose S | No | No | 7.7 | 348 | 2.68 k | 341,498 |
27 Mar 24 | Peter Rahmer | Common Stock | Sell | Dispose S | No | No | 7.7 | 298 | 2.29 k | 514,679 |
29 Jan 24 | Peter Rahmer | Common Stock | Sell | Dispose S | No | No | 9.64 | 1,651 | 15.92 k | 514,977 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
10 Apr 24
Relay Therapeutics: Q4 Earnings Insights
22 Feb 24
Relay Therapeutics Q4 2023 GAAP EPS $(0.67) Beats $(0.75) Estimate
22 Feb 24
Earnings Scheduled For February 22, 2024
22 Feb 24
Relay Therapeutics's Earnings: A Preview
21 Feb 24
Press releases
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
25 Apr 24
Treatment AI (CSE: TRUE) Unveils New AI-Powered Solutions Revolutionizing Medical Education
18 Apr 24
Unleashing AI in Healthcare: The Game-Changing Partnership Between Treatment AI (CSE: TRUE) and aiXplain concurrent with Federal Momentum
16 Apr 24
Relay Therapeutics to Participate in Upcoming Investor Conferences
11 Apr 24
AI Transforms Healthcare Stocks in 2024: Revolutionizing Medicine Across the Globe
11 Apr 24